LYSSIKATOS JOSEPH P (CHIEF SCIENTIFIC OFFICER) sold 2.6% of their position (20K shares) of ENLIVEN THERAPEUTICS, INC. on the open market
Open‑market sale worth $535.1K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 2 sales
Filed: 1/22/2026ACC: 0001967150-26-000002
Officer· CHIEF SCIENTIFIC OFFICER
Since Feb 2026
-20K
Net shares
Net seller
$535.1K
Total sold
2
Open market trades
0B · 2S
2
Total transactions
20K disposed
Non-Derivative Transactions2
Common Stock
Indirect
Shares
−5.49K
Price / share
$26.37
Trade value
$144.81K
% of position
0.7%
1/20/2026
765.19K→759.70K
Common Stock
Indirect
Shares
−14.51K
Price / share
$26.90
Trade value
$390.28K
% of position
1.9%
1/20/2026
759.70K→745.19K
Total
Net shares
−20K
Net value
-$535.10K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 1/20/2026 | S · Sale | −5.49K | $26.37 | $144.81K | 0.7% | 765.19K | 759.70K |
| Common Stock Indirect | 1/20/2026 | S · Sale | −14.51K | $26.90 | $390.28K | 1.9% | 759.70K | 745.19K |
| Total | −20K | -$535.10K | ||||||
Derivative Transactions0
No derivative transactions reported